Shionogi, a Japanese pharmaceutical company, announced at the European Conference on clinical microbiology and infectious diseases that the results of phase IIB study of drugs showed “rapid clearance” of covid-19 virus.
Yanyeyi’s covid-19 drug s-217622 was jointly developed by Hokkaido University and yanyeyi. The drug principle is similar to Pfizer covid-19 drug paxlovid, which inhibits virus self replication by inhibiting 3CL protease activity. Earlier, it was reported that the efficacy of this Japanese covid-19 oral drug “ensitrelvir (s-217622)” exceeded several oral drugs produced in the United States, and the final cure rate could reach 100%.
According to the theme database of financial Associated Press, among the relevant listed companies:
Apeloa Pharmaceutical Co.Ltd(000739) said that it has cooperated with yanye for many years in cdmo business.
Zhejiang Zhongxin Fluoride Materials Co.Ltd(002915) ranks first in the production capacity of trifluoro and tetrafluorobenzene intermediates, including an annual production capacity of 100 tons of 1,2,4-trifluorobenzene, which can be used as raw materials for the manufacture of s217622, the main component inhibitor of yanyeyi special drug.
